News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Theradiag Acquires Prestizia and Its Highly Innovative MicroRNA Technology Platform


6/27/2012 9:33:56 AM

PARIS--(BUSINESS WIRE)--Theradiag, the theranostics and in vitro diagnostics company focused on autoimmune disease, today announced that it is acquiring Prestizia, a biotechnology company that is developing a microRNA1 technology. “The acquisition of Prestizia represents a major advance for Theradiag. Its microRNA platform is going to allow us to strengthen our development in theranostics with a highly innovative, patented technology,” stated Michel Finance, CEO of Theradiag.

Read at BioSpace.com

comments powered by Disqus
Theradiag
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES